Discussion Forums > Working Towards a Cure

Bluebird Bio Releases Data on Current Gene Therapy Trials

<< < (36/39) > >>

Andy Battaglia:
Professor Cavazzana is the primary investigator of the HGB-205 study for bluebird.

Parin:
bluebird bio’s LentiGlobin™ Gene Therapy Granted Accelerated Assessment by European Medicines Agency for the Treatment of Transfusion-Dependent β-Thalassemia

http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bios-lentiglobintm-gene-therapy-granted-accelerated

Andy Battaglia:
It's very close to a reality.

Parin:
Yes, any idea about USA?

Andy Battaglia:
No idea yet about the US, but the reason why Europe was chosen first is explained in a very in depth article at http://www.pmlive.com/pharma_intelligence/Bluebird_Bio_on_the_cusp_of_a_gene_therapy_revolution_1246188

Navigation

[0] Message Index

[#] Next page

[*] Previous page